Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beyond COVID-19: Ousted BARDA Chief’s Whistleblower Complaint Suggests Widespread Politicization of HHS Funding Decisions

Executive Summary

Ousted BARDA Director Rick Bright's whistleblower complaint cites a long-pattern of political interference in scientific decisions making and could lead to overhauls in how BARDA and other HHS contracts are awarded to the drug industry. It could also impact how Congress funds BARDA, following a recent move by lawmakers to give the division more direct control of its funding. 

You may also be interested in...



Warp Speed May Be Usurping BARDA, Potentially Hurting COVID-19 Vaccine Prospects

Congress wants HHS to explain why BARDA scientists were removed from leadership positions on COVID-19 vaccine contracts. It is just one of multiple examples of Democrats raising concerns that Operation Warp Speed could be hurting, not helping the COVID-19 response effort.

Coronavirus Notebook: BARDA Contracting Scrutiny; Part D Cost Sharing

Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.

COVID-19 Funds Flow To Startup In Bid To Restore US Pharmaceutical Manufacturing

Trump administration infuses Phlow with potentially $800m-plus for fully integrated domestic manufacture of essential medicines for COVID-19 and other crises. Key figures in new approaches to securing drugs and experts on China helped frame the project’s approach.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel